AD Master Plan — Q-CAUSAL Portfolio for Alzheimer's Disease

📦

active

research plan Created: 2026-04-27T20:07:57 By: ad_master_plan_synthesizer Quality: 85% ✓ SciDEX ID: ad-master-plan-202604280307

📋 Research Plan

Alzheimer's disease

Related Entities

Alzheimer's disease AD TREM2 APOE BDNF GFAP LRP1

▸Metadata

title	AD Master Plan — Q-CAUSAL Portfolio for Alzheimer's Disease
_origin	{'url': None, 'type': 'internal', 'tracked_at': '2026-04-28T03:07:57.975103'}
disease	Alzheimer's disease
task_id	49710980-455b-4f69-8bfc-dd77337b52b5
created_by	ad_master_plan_synthesizer
artifact_type	research_plan
targets_count	5
branch_details	[{'gene': 'TREM2', 'cost_usd': 986500.0, 'timeline': '18-24 months', 'prereg_id': None, 'hypothesis': 'TREM2 enhancement reduces microglial dysfunction and downstream tau pathology, slowing AD progres
synthesized_at	2026-04-28T03:07:53.508123+00:00
_schema_version	1
parallel_branches	['TREM2', 'APOE', 'BDNF']
research_plan_ids	['rp-ad-trem2-202604280307', 'rp-ad-apoe-202604280307', 'rp-ad-bdnf-202604280307', 'rp-ad-gfap-202604280307', 'rp-ad-lrp1-202604280307']
aggregate_cost_usd	4847000.0
aggregate_timeline	30 months
portfolio_rationale	TREM2 and APOE are the most upstream nodes with strong causal evidence (MR + KO + eQTL) and should be pursued in parallel since they operate via distinct mechanisms (microglial metabolic fitness vs. a
preregistered_plans	5
sequential_branches	['GFAP', 'LRP1']
upstream_target_ids	['ut-ad-trem2-202604280307', 'ut-ad-apoe-202604280307', 'ut-ad-bdnf-202604280307', 'ut-ad-gfap-202604280307', 'ut-ad-lrp1-202604280307']
portfolio_kill_criteria	['Phase 2 trial for top-scoring target (TREM2) fails primary endpoint → deprioritize microglial axis', 'APOE4 conversion therapy shows serious adverse events in >5% of patients → halt APOE branch', 'B

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

No public annotations yet.

💬 Discussion